Life Sciences
Life Sciences: The Latest
  • EU Highlights
  • Viewpoints

Dutch universities square off with Elsevier

With open access talks failing to break new ground, the Netherlands’ university association calls for researchers to consider giving up their posts with Elsevier journals

Irish national Pierre Meulien appointed to run Innovative Medicines Initiative

The current head of Genome Canada will take over as executive director of the world’s largest pharmaceuticals public-private partnership in September

Europe’s biotech companies unite to fight antimicrobial resistance

The BEAM Alliance – Biotechs from Europe innovating in Antimicrobial Resistance - brings together 37 companies from ten countries to accelerate progress in dealing with drug-resistant infections

Patents can make or break drug discovery in Poland

There are several barriers holding back science-industry collaboration, but the most urgent one is the reluctance to protect intellectual property in advance of publishing research results, according to two of Poland’s leading patent attorneys

Patients should have more control over their health

Smartphones can help you understand and look after your health says Bruce Hellman, chief executive of health app start-up uMotif

Our research saves lives – if you let us

A new EU data protection law risks killing some types of medical research, researchers at the Karolinska Institutet say. Their prescription: A law that regulates Big Data, but allows for research

Life Sciences Archive
Cambridge researchers and pharma in innovative new consortium to develop and study early stage drugs
An innovative new Consortium will act as a ‘match-making’ service between pharmaceutical companies and researchers in Cambridge with the aim of...
Biogen enters collaboration with the Parkinson’s Institute and Clinical Center
The collaboration aims to enhance disease understanding and increase the pace of discovery of new therapeutics
Imperial College London: New biomedical engineering centre gets planning green light
Hammersmith and Fulham Council has granted planning permission for construction of the Michael Uren Biomedical Engineering Research Hub.
Dutch universities square off with Elsevier
With open access talks failing to break new ground, the Netherlands’ university association calls for researchers to consider giving up their...
Warwick University: C Cancer drug 49 times more potent than Cisplatin
Tests have shown that a new cancer drug, FY26, is 49 times more potent than the clinically used treatment Cisplatin.
Page 1 of 685> 1 2 3  ... 
Innovation in Progress - Science|Business Network

Cambridge researchers and pharma in innovative new consortium to develop and study early stage drugs

An innovative new Consortium will act as a ‘match-making’ service between pharmaceutical companies and researchers in Cambridge with the aim of developing and studying precision medicines for some of the most globally devastating diseases.

Biogen enters collaboration with the Parkinson’s Institute and Clinical Center

The collaboration aims to enhance disease understanding and increase the pace of discovery of new therapeutics

Imperial College London: New biomedical engineering centre gets planning green light

Hammersmith and Fulham Council has granted planning permission for construction of the Michael Uren Biomedical Engineering Research Hub.

Horizon 2020 Special Coverage
Unlocking the value of Personalised Healthcare in Europe
This new study shows ICT investments could cut healthcare costs for key ailments by more than 35%.
Bigger and Simpler: A short guide to the EU's €80 billion Horizon 2020 programme
A two-year political fight formally began in Brussels on 30 November with the publication of the European Commission's plan for Horizon 2020, its omnibus R&D programme. It promises less red tape, broader benefits, and more jobs and economic growth.
Biofuels: The Next Generation
Key ideas and recommendations to accelerate the deployment of sustainable biofuels have emerged at the second in a series of three high-level academic policy debates on the energy R&D challenge, The Energy Difference
Advertisement